Physician profile
Khashayar Hematpour
NPI 1902065543
$107,815.26
in general payments reported to CMS, 2019-2025
24 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $16K · 2021: $6,939 · 2022: $27K · 2023: $14K · 2024: $5,052 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $14K · Travel and Lodging: $8,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,277.20 |
| Food and Beverage | $14,148.09 |
| Travel and Lodging | $8,317.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $62,484.78 | 2019-2025 | Amplatzer Amulet, Advisor, Aveir |
| Boston Scientific Corporation | $21,761.53 | 2019-2025 | Watchman Access System, Bodyguardian, Essentio Sr |
| Biosense Webster, INC. | $16,937.39 | 2019-2025 | Carto 3, Octaray Mapping Catheter, Nuvision Ice Catheter |
| Medical Device Business Services, INC. | $1,750.00 | 2019 | |
| Medtronic, INC. | $1,656.62 | 2023-2025 | Evera Mri Xt Dr Surescan, Aurora Ev-Icd Mri Surescan, Selectsecure |
| Cardiva Medical, INC. | $639.23 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $582.46 | 2019-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $313.22 | 2021-2024 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $272.89 | 2019 | |
| Elutia, INC. | $249.65 | 2020-2022 | |
| Atricure, INC. | $215.35 | 2019-2023 | |
| Pfizer INC. | $211.67 | 2019-2025 | |
| Amgen INC. | $184.80 | 2020-2023 | Repatha |
| Biotronik INC. | $119.66 | 2023 | Edora 8 Dr-T |
| Astrazeneca Pharmaceuticals LP | $118.04 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $81.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.70 | 2021-2023 | Eliquis, Camzyos |
| Irhythm Technologies, INC. | $41.68 | 2024 | Zio Xt Patch, Zio Monitor |
| Cordis US Corp. | $34.30 | 2024 | Mynx Control |
| Sanofi-Aventis U.S. LLC | $29.23 | 2022 | |
| Baylis Medical Company INC | $17.88 | 2021 | |
| Chiesi USA, INC. | $16.46 | 2025 | Kengreal |
| Abiomed | $14.42 | 2020 | |
| Convatec INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khashayar Hematpour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.